drugset / Trial / NCT05089617
To Evaluate the Safety, Tolerability, and Pharmacokinetics of YG1699（Antidiabetic） in Healthy Chinese Sbjects
RandomizedSequentialTriple-blindTreatment
Summary
This is a randomized, double-blind, placebo-controlled, single ascending dose (SAD) and multi-dose, sequential, bridging study in healthy volunteer using YG1699 .
Timeline
- Start
- 2022-01-09
- Primary completion
- 2022-08-12
- Completion
- 2022-08-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | YG1699 | Small molecule | 5 mg | Oral |
| Subject | YG1699 | Small molecule | 20 mg | Oral |
| Subject | YG1699 | Small molecule | 25 mg | Oral |